AI Verdict
MSFT has stronger fundamentals based on our AI analysis.
IMRX vs MSFT Fundamental Comparison
| Metric | IMRX | MSFT |
|---|---|---|
| Revenue | $0.0 | $158.9B |
| Net Income | $-56.0M | $66.2B |
| Net Margin | N/A | 41.7% |
| ROE | -25.6% | 16.9% |
| ROA | -24.2% | 10.0% |
| Current Ratio | 17.50x | 1.39x |
| Debt/Equity | 0.00x | 0.10x |
| EPS | $-1.27 | $8.87 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IMRX vs MSFT: Frequently Asked Questions
Is IMRX or MSFT a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MSFT has stronger fundamentals. IMRX is rated SELL (72% confidence) while MSFT is rated BUY (91% confidence). This is not investment advice.
How does IMRX compare to MSFT fundamentally?
Immuneering Corp has ROE of -25.6% vs MICROSOFT CORP's 16.9%. Net margins are N/A vs 41.7% respectively.
Which stock pays higher dividends, IMRX or MSFT?
IMRX has a dividend yield of N/A or no dividend while MSFT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IMRX or MSFT for long term?
For long-term investing, consider that IMRX has SELL rating with 72% confidence, while MSFT has BUY rating with 91% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IMRX vs MSFT?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IMRX vs MSFT, the AI consensus favors MSFT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.